BNP Paribas Financial Markets Grows Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

BNP Paribas Financial Markets increased its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 152.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 123,333 shares of the biopharmaceutical company’s stock after purchasing an additional 74,522 shares during the period. BNP Paribas Financial Markets’ holdings in Esperion Therapeutics were worth $203,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ESPR. BOKF NA purchased a new position in shares of Esperion Therapeutics in the second quarter valued at approximately $26,000. Xponance Inc. acquired a new position in shares of Esperion Therapeutics during the 2nd quarter valued at about $28,000. Traphagen Investment Advisors LLC acquired a new stake in Esperion Therapeutics during the third quarter worth about $27,000. National Bank of Canada FI boosted its holdings in Esperion Therapeutics by 115.9% in the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 10,225 shares during the last quarter. Finally, Sivia Capital Partners LLC acquired a new stake in shares of Esperion Therapeutics during the 2nd quarter worth approximately $44,000. 47.39% of the stock is owned by hedge funds and other institutional investors.

Esperion Therapeutics Stock Up 3.6 %

NASDAQ:ESPR opened at $2.33 on Tuesday. The company has a market cap of $459.09 million, a price-to-earnings ratio of -3.64 and a beta of 1.01. The company has a fifty day simple moving average of $2.39 and a two-hundred day simple moving average of $2.22. Esperion Therapeutics, Inc. has a 52 week low of $1.58 and a 52 week high of $3.94.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a report on Thursday, December 12th. StockNews.com cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Needham & Company LLC reissued a “buy” rating and set a $6.00 target price on shares of Esperion Therapeutics in a research note on Friday.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.